SNAP-8 (Acetyl Octapeptide-3)
⚠️ Disclaimer: For Research Use Only. Not for human administration or clinical therapy.
Basic Information
- CAS No.: 868844-74-0
- Sequence: Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂ (Ac-EEMQRRAD-NH₂), synthetic acetylated octapeptide
- Molecular Formula: \(\boldsymbol{C_{41}H_{70}N_{16}O_{16}S}\)
- Molecular Weight: 1075.16 g/mol
- Appearance: White to off-white lyophilized powder
- Solubility: Soluble in sterile water, aqueous cosmetic buffers
- Storage: Lyophilized powder stored at -20℃, protected from light and moisture, avoid repeated freeze-thaw cycles. After reconstitution, refrigerate and use promptly.
Development Background
SNAP-8, INCI name Acetyl Octapeptide-3, was developed by Lipotec (now Lubrizol). It is an optimized longer analog of Argireline (Acetyl Hexapeptide-8). It mimics the N-terminal fragment of SNAP-25 protein, designed to interfere with SNARE complex assembly. Compared with Argireline, it shows stronger binding affinity for SNARE complex in research tests.
Mechanism of Action (Research Findings)
- Mimics the N-terminal domain of SNAP-25 protein, competitively binds to SNARE complex components (SNAP-25, syntaxin, synaptobrevin/VAMP).
- Partially inhibits SNARE complex formation, reduces synaptic vesicle fusion and acetylcholine release at neuromuscular junctions.
- Attenuates facial muscle micro-contraction, for studying dynamic expression wrinkles (crow’s feet, forehead lines, glabellar lines).
- Reversible competitive inhibition. It does not cleave SNAP-25 protein, different from irreversible botulinum toxin.
- Terminal modifications (N-Acetylation, C-amidation) improve peptide stability against peptidase degradation.
Research Areas
- SNARE complex & synaptic vesicle exocytosis research
- In vitro neurotransmitter release model
- Anti-wrinkle / expression line cosmetic peptide research
- Structure-activity comparison with Argireline
- Peptide delivery & formulation stability study








评价
目前还没有评价